Abstract:Background: Bencycloquidium bromide (BCQB) is a novel, potent and selective muscarinic M1/M3 receptor antagonist under development for the treatment of rhinorrhea in rhinitis. The pharmacokinetics and safety of BCQB in animals have been established in preclinical studies. However, no clinical pharmacokinetic data are available for BCQB in humans. Objective: The aim of this first-in-human study was to evaluate the pharmacokinetics, safety and tolerability of BCQB following single and multiple intranasal doses in healthy Chinese subjects. Methods: The clinical trial was comprised of the following four studies: (i) an open-label, single-dose escalation study to evaluate the safety and tolerability in healthy subjects after intranasal doses of BCQB ranging from 45 to 450 mg (total of six doses); (ii) an open-label, multiple-dose escalation study to assess the safety and tolerability in healthy subjects after intranasal administration with 120 and 150 mg doses of BCQB (360 and 450 μg/day) administered three times daily for 15 days; (iii) a randomized, open-label and parallel-group design to evaluate the single-dose pharmacokinetics of BCQB after intranasal dosing (45, 90, and 180 μg); and (iv) ten subjects received 120 μg of BCQB by intranasal administration, three times daily for 5 days with a final single dose on day 7 to assess its multiple-dose pharmacokinetics. Safety and tolerability of BCQB were evaluated by monitoring adverse events (AEs), ECG recordings, vital signs and clinical laboratory parameters. The pharmacokinetic parameters for BCQB were calculated by software using noncompartmental methods. Results: All AEs were mild, of limited duration and no more frequent at higher doses. There was no serious adverse event, death or withdrawal. No clinically significant change was noted in clinical laboratory parameters, cardiac parameters or vital signs. Following single intranasal dosing, BCQB was rapidly absorbed with a median time to maximum concentration (t max ) of 8 minutes for 45, 90, and 180 mg dose groups; the plasma concentration of BCQB decreased in a biphasic manner with the mean half-life (t 1/2 ) of 8.5 hours; the maximum concentration (C max ) and area under the plasma concentration-time curve (AUC) of BCQB increased linearly across the examined dose range of 45–180 μg. During the multiple dosing, the steady state was achieved within 3 days of 120 μg three times daily dosing of BCQB. A slightly greater AUC was observed after 5 days of multiple dosing, with the mean accumulation ratio of 1.26; however, the half-life was unchanged. Conclusion: BCQB was safe and well tolerated in healthy Chinese subjects when administered intranasally with single and multiple doses across the doses studied. The mean C max and AUC increased proportionally to the studied doses, and the steady state was achieved within 3 days after three times daily dosing. A slight accumulation of BCQB following multiple dosing was observed. The pharmacokinetics, safety and tolerability profiles of BCQB pose it as a good candidate for further development in the treatment of rhinorrhea in rhinitis.

Characterization of bencycloquidium bromide, a novel muscarinic M3 receptor antagonist in guinea pig airways

M3 muscarinic receptor antagonist bencycloquidium bromide attenuates allergic airway inflammation, hyperresponsiveness and remodeling in mice

Safety, Tolerability and Pharmacokinetics of Bencycloquidium Bromide, a Novel Inhaled Anticholinergic Bronchodilator, in Healthy Subjects: Results from Phase I Studies

Effects of Chuankezhi Injection on Airway Inflammation in Mouse Model of Asthma and Isolated Guinea-Pig Airway Smooth Muscle

Effects of the Inhalation of the M3 Receptor Antagonist Bencycloquidium Bromide in A Mouse Cigarette Smoke-Induced Airway Inflammation Model.

Pharmacokinetics, Safety and Tolerability of Bencycloquidium Bromide, a Novel Selective Muscarinic M1/M3 Receptor Antagonist, after Single and Multiple Intranasal Doses in Healthy Chinese Subjects

Design and synthesis of 2-(2,2-diarylethyl)-cyclamine derivatives as M3 receptor antagonists and functional evaluation on COPD

New promising agents against COPD and asthma among the amides of 1-oxo-3-phenyl-isochroman-6-carboxylic acid

Discovery of Biphenyl Piperazines As Novel and Long Acting Muscarinic Acetylcholine Receptor Antagonists

In vitro metabolism of bencycloquidium bromide and its inhibitory effects on human P450 isoenzymes: implication of CYP2D6, CYP2C19 and CYP3A4/5

Molecular hybridization yields triazole bronchodilators for the treatment of COPD

Binding modes and pharmacophoric features of muscarinic antagonism and β2 agonism (MABA) conjugates

[Muscarinic Receptor Subtypes in Respiratory Center and Their Functions].

Effects of Phosphodiesterase 4 Inhibitor on Cough Response in Guinea Pigs Sensitized and Challenged with Ovalbumin

Effects of the Selective Muscarinic Receptor Antagonist Penehyclidine Hydrochloride on the Respiratory Tract.

Discovery Of Novel Potent Muscarinic M-3 Receptor Antagonists With Proper Plasma Stability By Structural Recombination Of Marketed M-3 Antagonists

[The Effect of Bradykinin B(2) Receptor Antagonist on Cough Reactivity in a Sensitized Guinea Pig Model].

Aclidinium Bromide Holds Promising Inhibitory Effects in A549 Lung Cancer Cells Potentials by Regulating PI3K / AKT Signaling Pathway.

Investigating the Unbinding of Muscarinic Antagonists from the Muscarinic 3 Receptor

Phosphodiesterase 3 Inhibitor Attenuates Cough Response in a Sensitized Guinea Pig Model

Effect of Ipratropium Bromide on Airway and Pulmonary Muscarinic Receptors in a Rat Model of Chronic Obstructive Pulmonary Disease